In this review:
Pragmatic open-label PrEP trial in MSM
On-demand PrEP with oral tenofovir/emtricitabine
Near elimination of HIV transmission with PrEP and ART
PrEP in San Francisco and HIV incidence
PrEP and potential harms
Rilpivirine/emtricitabine/tenofovir for PEP
TAF vs. TDF: virological response
Cabotegravir + rilpivirine as oral maintenance
Maturation inhibitor mechanisms, GSK2838232 and BMS-986001
Serosorting and seroadaptive behaviour
Statins and CV changes
Abacavir and MI risk
Antiretroviral exposure and CKD
TAF vs. TDF: renal/bone safety
Please login below to download this issue (PDF)